

INTERNAL MEDICINE GRAND ROUNDS

TITLE:

FGF23 at the Intersection of Kidney and Cardiovascular Disease

SPEAKER:

Myles Wolf, M.D., MMSc

DATE:

Wednesday, January 11, 2023

TIME:

12:00 pm to 1:00 pm

LOCATION:

Waitzer Hall, Suite 300, and Virtually through Zoom:

<https://bit.ly/3qjdBoN>

OBJECTIVES:

- Discuss the role of FGF23 in normal mineral metabolism and in chronic kidney disease.
- Identify the off-target cardiovascular effects of FGF23.
- Evaluate mechanisms of FGF23 regulation.

COMPETENCIES:

Patient Care, Medical Knowledge

AUDIENCE:

Internists, family practitioners, fellows, residents, medical students, allied health professionals and community physicians

**Myles Wolf, M.D., MMSc**

Charles Johnson, M.D. Distinguished Professor of Medicine Chief, Division of Nephrology, Department of Medicine
Duke University School of Medicine

Myles Wolf is the Charles Johnson, MD, Distinguished Professor of Medicine and Chief of the Division of Nephrology at the Duke University School of Medicine. Dr. Wolf received his MD from the State University of New York–Downstate, completed Internal Medicine and Nephrology training at Massachusetts General Hospital, and obtained a Master of Medical Sciences degree in Clinical and Physiological Investigation from Harvard Medical School. Dr. Wolf mentors, manages, and leads ~50 clinical and research faculty, ~15 nephrology fellows, 6 advanced practice practitioners, an administrative and research staff of >30 professionals, and many rotating students and postdoctoral PhD trainees. Managing an annual operating budget of more than \$15M, Dr. Wolf is responsible for developing the vision and executing the operational strategy of Duke Nephrology across its clinical, research and educational missions. In recognition of his scientific contributions, Dr. Wolf was elected to the American Society of Clinical Investigation in 2010, the Association of American Physicians in 2017 and the American Clinical and Climatological Society in 2021. He received the 2014 Young Investigator Award from the American Society of Nephrology, and was elected to the Council of the International Society of Nephrology in 2017 and as Chair of its North American and Caribbean Regional Board in 2019. In 2020, Dr. Wolf was appointed to the Board of Directors of Akebia Therapeutics, Inc., for which he serves as Chair of the Research and Development Committee.

ACCREDITATION

Eastern Virginia Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Eastern Virginia Medical School designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE

Myles Wolf, M.D., MMSc serves a consultant for Pharmacosmos, Launch, and Enyo. He is a member of the Scientific Advisory Board for Walden and Unicycive. He is on the Board of Directors for Akebia Therapeutics, Inc. All financial relationships have been mitigated. The planning committee members have no relevant financial relationships with ineligible companies to disclose.